Gliknik raises $4.9 million in Series B financing

  Gliknik Inc., a privately-held biopharmaceuticals company creating new therapies for cancer and immune/inflammatory disorders, announced on October 22 it has raised $4.9 million in Series B Financing. Baxter Ventures, an initiative created in 2011 by Baxter International Inc., led the Series B raise and is joined by existing investors. With the funding, Gliknik will further advance toward the clinic its IVIG-mimetic lead compound, GL-2045, from its first-in-class stradomer platform. … Continue reading

BmoreMedia: Biotech firm Fyodor to begin trials for malaria test

  Fyodor Biotechnology Inc. expects to complete human trials on its product to detect malaria next year, with commercial production to begin in 2014. The Baltimore biotech firm is also in the planning stages for a second product, a variation of the first, that should be ready for production by 2015. The tests are significant for diagnosis and treatment of an illness that is endemic in developing countries around the … Continue reading

Fyodor Biotechnologies expands within University of Maryland BioPark

  Fyodor Biotechnologies Inc. announced on August 16 it has expanded its office and laboratory space at the University of Maryland BioPark in Baltimore, moving from the BioPark’s BioInnovation Center (BIC) at 801 West Baltimore Street to the expanded BioInnovation Center across the street at 800 West Baltimore Street. The move is prompted by Fyodor’s advancing research and development activities, including those related to its urine-based malaria diagnostic assay. “The … Continue reading

JHU and Fraunhofer Heinrich Hertz Institute team up

  The Johns Hopkins University (JHU), America’s first research university, in Baltimore, Md., and the Fraunhofer Heinrich Hertz Institute (HHI), a mobile and information technology development leader based in Berlin, Germany, have signed a Memorandum of Understanding to jointly research the innovative medical applications of integrated optical sensors: small, highly sensitive devices with disease-recognition capabilities. Under the terms of this agreement – signed on June 19 at the 2012 BIO … Continue reading

Noxilizer wins best life sciences company award

  Noxilizer, located at the UMBC Technology Center, won Best Life Sciences Company in the Maryland Incubator Company of the Year awards. The award, announced at the Center Club June 14, recognizes the best company involved in biotechnolgy or life sciences industry. Chosen among three finalists, Noxilizer has a unique and superior NO2-based sterilization technology that is revolutionizing two major sterilization markets – medical device/pharmaceutical/biotechnology manufacturing and hospitals, according to … Continue reading

New York Times: Drug Helps Defense System Fight Cancer

  By ANDREW POLLACKPublished: June 1, 2012 CHICAGO – One of the great frustrations for researchers in the war on cancer is that the body’s own defense system does not do a better job fighting the disease. Tumors, it turns out, have a molecular shield that repels attacks from the immune system. Now, a new study says, an experimental drug is showing promise in disabling that shield, unleashing the immune … Continue reading

Profectus receives grant to develop vaccine for Nipah and Hendra viruses

Profectus BioSciences, Inc. (Profectus), a leader in the development of therapeutic and preventive vaccines against infectious diseases and cancers, announced May 2 it received a grant under the Partnerships for Biodefense RFA from the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH. This $5.6M award supports the preclinical development of Hendra virus soluble G (HeV?sG) as a vaccine for use in humans against either … Continue reading

Profectus receives grant to develop vaccine for Ebola and Marburg viruses

  Profectus BioSciences, Inc., a leader in the development of therapeutic and preventive vaccines against infectious diseases, and the Galveston National Laboratory (GNL) at the University of Texas Medical Branch at Galveston announced May 2 they received a five-year $5.4 million grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH). The grant will support development of a trivalent vaccine … Continue reading

David Block, CEO of Gliknik, to chair GBC Bioscience Committee

  The Greater Baltimore Committee announced June 5 David S. Block, MD, president and CEO of Gliknik, Inc. has been named chair of the Greater Baltimore Committee’s Bioscience Committee. Dr. Block was chosen because of his leadership in the greater Baltimore bioscience community and his history of successful bioscience entrepreneurship. “A key priority for this committee going forward will be supporting the creation and growth of innovative bioscience companies by … Continue reading